Bionic Sight Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 4

Bionic Sight General Information

Description

Developer of a medical device designed to develop and commercialize prosthetic treatments for blindness due to retinal degenerative disease. The company's device uses code that can convert visual images into similar patterns of an action potential that the retina normally produces and can do so across a broad range of stimuli including faces, landscapes, and movement, essentially replicating patterns in a code the brain is expecting and can recognize, enabling users to bring prosthetic capabilities up to the level of near-normal image representation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 430 East 63rd Street
  • Apartment 2-G
  • New York, NY 10065-7923
  • United States
+1 (646)
Primary Industry
Therapeutic Devices
Vertical(s)
Corporate Office
  • 430 East 63rd Street
  • Apartment 2-G
  • New York, NY 10065-7923
  • United States
+1 (646)

Bionic Sight Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bionic Sight Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 01-Feb-2025 Completed Clinical Trials - General
4. Later Stage VC (Series A) 06-Jun-2022 Completed Clinical Trials - General
3. Later Stage VC 01-Mar-2020 Completed Clinical Trials - General
2. Later Stage VC 02-Feb-2017 $2M $2M Completed Clinical Trials - General
1. Early Stage VC 01-Jan-2014 Completed Clinical Trials - General
To view Bionic Sight’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Bionic Sight Patents

Bionic Sight Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023307691-A1 An optogenetic gene therapy for treating blindness Pending 09-Jul-2022
EP-4551243-A1 An optogenetic gene therapy for treating blindness Pending 09-Jul-2022

Bionic Sight Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bionic Sight Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Raptor Group Venture Capital Minority
Samsara BioCapital Venture Capital Minority
Beacon Therapeutics VC-Backed Company Minority
Partnership Fund for New York City Impact Investing Minority
To view Bionic Sight’s complete investors history, request access »

Bionic Sight FAQs

  • When was Bionic Sight founded?

    Bionic Sight was founded in 2012.

  • Where is Bionic Sight headquartered?

    Bionic Sight is headquartered in New York, NY.

  • What is the size of Bionic Sight?

    Bionic Sight has 5 total employees.

  • What industry is Bionic Sight in?

    Bionic Sight’s primary industry is Therapeutic Devices.

  • Is Bionic Sight a private or public company?

    Bionic Sight is a Private company.

  • What is Bionic Sight’s current revenue?

    The current revenue for Bionic Sight is .

  • How much funding has Bionic Sight raised over time?

    Bionic Sight has raised $10.2M.

  • Who are Bionic Sight’s investors?

    Raptor Group, Samsara BioCapital, Beacon Therapeutics, and Partnership Fund for New York City have invested in Bionic Sight.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »